Design and Development of Innovative Formulations of Resatorvid for Targeted Skin Drug Delivery and Applications Therein

Case ID:

University of Arizona researchers have developed a novel formulation of Resatorvid, a selective TLR4 inhibitor that was originally designed for the treatment of sepsis. This re-formulation is designed for delivery to the skin for a variety of skin diseases including early stages of skin cancer.

Skin cancers tend to be slow growing and can be cured with early and adequate treatment. Non-melanoma skin cancer is the most common neoplasm in countries with high rates in caucasian populations and in cases of high UV ray exposure. In the United States alone, there are more than half a million new cases per year. Despite the fatality rate of non-melanoma skin cancer being minimal, it is known to cause significant impact including severe local destruction, permanent disfigurement and disability.

Currently, there are several recommended preventive measures for skin cancer including recommendations for avoiding UV rays from the sun or tanning beds, utilizing broad spectrum sunscreen and scheduling routine dermatologist examinations. Even with these preventive measures available to most, skin cancers cases are still bountiful. The need for more advanced preventive measures would significantly reduce the amount of cases yearly.


  • Prevention of non-melanoma skin cancers


  • Hydrophobic
  • Can use various platforms (serum, lotion, etc)
  • Selectivity (selective inhibition of TLR4)
  • Topical
  • Targeted drug delivery
  • “First in class” therapeutic
Patent Information:
Contact For More Information:
Katherine Kuhns
Licensing Manager, UAHS-TLA
The University of Arizona
Lead Inventor(s):
Heidi Mansour
Victor Ruiz
Sally Dickinson
Clara Curiel
Hsiao-Hui Chow
Georg Wondrak